Hyperfine (NASDAQ:HYPR) Announces Earnings Results, Hits Estimates

Hyperfine (NASDAQ:HYPR) released its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09), FiscalAI reports. Hyperfine had a negative return on equity of 99.81% and a negative net margin of 210.75%.The firm had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $4.13 million.

Here are the key takeaways from Hyperfine’s conference call:

• Revenue rose 45% year over year to $3.9 million in Q2, while system sales increased 50% to 12 units; first-half revenue reached $7.8 million.
• Gross margin remained above 50% for the fourth consecutive quarter at 50.7%, while first-half cash burn improved approximately 9% year over year to $16.6 million.
• Management reiterated 2026 revenue guidance of $20 million to $22 million, gross margin of 50% to 55%, cash burn of $26 million to $28 million, and cash runway extending into 2028.
• Growth is broadening across hospitals and IDNs, neurology offices, and international markets; the company cited initial large-IDN adoption, more than a dozen office placements, and first European Model 2 sales.
• Hyperfine remains loss-making, reporting a $9.3 million quarterly net loss, and its stronger cash position partly reflects $10.6 million raised through its ATM program, which may create shareholder dilution.

Hyperfine Stock Down 2.7%

Shares of NASDAQ HYPR traded down $0.03 during mid-day trading on Friday, reaching $0.95. The company had a trading volume of 904,666 shares, compared to its average volume of 732,139. The company has a current ratio of 5.52, a quick ratio of 4.90 and a debt-to-equity ratio of 0.38. The firm has a 50 day simple moving average of $1.23 and a two-hundred day simple moving average of $1.25. The stock has a market cap of $94.80 million, a P/E ratio of -2.51 and a beta of 1.42. Hyperfine has a 52-week low of $0.85 and a 52-week high of $2.22.

Analyst Ratings Changes

A number of brokerages have commented on HYPR. B. Riley Financial reissued a “buy” rating on shares of Hyperfine in a research report on Wednesday, May 13th. BTIG Research started coverage on Hyperfine in a research note on Wednesday, April 29th. They issued a “buy” rating and a $2.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperfine in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $1.78.

Hedge Funds Weigh In On Hyperfine

Several hedge funds have recently made changes to their positions in HYPR. Vanguard Group Inc. lifted its holdings in shares of Hyperfine by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock valued at $5,092,000 after purchasing an additional 190,136 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Hyperfine by 21.4% in the 4th quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock valued at $799,000 after purchasing an additional 143,975 shares during the last quarter. Cerity Partners LLC acquired a new position in Hyperfine in the 4th quarter valued at $59,000. Renaissance Technologies LLC boosted its holdings in shares of Hyperfine by 674.4% in the fourth quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock valued at $357,000 after acquiring an additional 317,645 shares in the last quarter. Finally, State Street Corp increased its position in Hyperfine by 6.1% during the 4th quarter. State Street Corp now owns 265,195 shares of the company’s stock worth $260,000 after purchasing an additional 15,200 shares during the period. Hedge funds and other institutional investors own 15.03% of the company’s stock.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.